Johnson & Johnson (JNJ) Quick Ratio (Acid-Test): 0.77
Is Johnson & Johnson’s quick ratio (acid-test) high or low?
Johnson & Johnson's quick ratio (acid-test) of 0.77 is 15% below its 5-year average of 0.91, near the low end of its 5-year range (0.77–1.12).
The quick ratio (acid-test) for Johnson & Johnson (JNJ) is 0.77 as of Wednesday, June 10, 2026. It is below its 12-month average by 5.52% (0.81).
JNJ Quick Ratio (Acid-Test) Chart
JNJ Average Quick Ratio (Acid-Test) Chart
JNJ Current vs Average Quick Ratio (Acid-Test) Chart
JNJ Quick Ratio (Acid-Test) Metrics
QUICK RATIO (ACID-TEST)
0.77
QUICK RATIO (ACID-TEST) AVG TTM
0.81
QUICK RATIO (ACID-TEST) AVG 3Y
0.84
QUICK RATIO (ACID-TEST) AVG 5Y
0.91
QUICK RATIO (ACID-TEST) AVG 10Y
1.17
QUICK RATIO (ACID-TEST) AVG 15Y
1.39
QUICK RATIO (ACID-TEST) AVG 20Y
1.41
CURRENT VS TTM AVG
-5.52%
CURRENT VS 3Y AVG
-8.06%
CURRENT VS 5Y AVG
-15.38%
CURRENT VS 10Y AVG
-33.98%
CURRENT VS 15Y AVG
-44.70%
CURRENT VS 20Y AVG
-45.45%
JNJ Competitors' Quick Ratio (Acid-Test)
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Johnson & Johnson (JNJ) | — | 0.77 | 0.81 | 0.84 | 0.91 |
| Pfizer Inc. (PFE) | $146.36B | 0.87 | 0.90 | 0.87 | 0.95 |
| Merck & Co., Inc. (MRK) | $293.02B | 1.30 | 1.23 | 1.17 | 1.09 |
| AbbVie Inc. (ABBV) | $399.54B | 0.56 | 0.56 | 0.68 | 0.69 |
| Eli Lilly and Company (LLY) | $1.07T | 1.19 | 1.04 | 0.90 | 0.94 |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 1.14 | 1.15 | 1.19 | 1.27 |
Liquidity Comparison
Quick Ratio
0.77
Excludes inventory
Current Ratio
1.03
Includes inventory
Johnson & Johnson Quick Ratio (Acid-Test) Formula & Definition
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Johnson & Johnson Quick Ratio (Acid-Test) FAQ
- What is the quick ratio (acid-test) for Johnson & Johnson (JNJ)?
- The quick ratio (acid-test) for JNJ stock is 0.77.
- Is Johnson & Johnson's quick ratio (acid-test) high or low?
- Johnson & Johnson's quick ratio (acid-test) of 0.77 is 15% below its 5-year average of 0.91, near the low end of its 5-year range (0.77–1.12).
- What is the TTM average quick ratio (acid-test) for Johnson & Johnson (JNJ)?
- The TTM average quick ratio (acid-test) for JNJ stock is 0.81.
- What is the 3Y average quick ratio (acid-test) for Johnson & Johnson (JNJ)?
- The 3Y average quick ratio (acid-test) for JNJ stock is 0.84.
- What is the 5Y average quick ratio (acid-test) for Johnson & Johnson (JNJ)?
- The 5Y average quick ratio (acid-test) for JNJ stock is 0.91.
- What is the 10Y average quick ratio (acid-test) for Johnson & Johnson (JNJ)?
- The 10Y average quick ratio (acid-test) for JNJ stock is 1.17.
- What is the 15Y average quick ratio (acid-test) for Johnson & Johnson (JNJ)?
- The 15Y average quick ratio (acid-test) for JNJ stock is 1.39.
- What is the 20Y average quick ratio (acid-test) for Johnson & Johnson (JNJ)?
- The 20Y average quick ratio (acid-test) for JNJ stock is 1.41.
Johnson & Johnson Quick Ratio (Acid-Test) History
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2025-12-28 | 0.77 |
| 2024-12-29 | 0.86 |
| 2023-12-31 | 0.91 |
| 2023-01-01 | 0.81 |
| 2022-01-02 | 1.12 |
| 2021-01-03 | 0.99 |
| 2019-12-31 | 1.01 |
| 2018-12-31 | 1.20 |
| 2017-12-31 | 1.12 |
| 2016-12-31 | 2.16 |
| 2015-12-31 | 1.88 |
| 2014-12-31 | 2.04 |
| 2013-12-31 | 1.89 |
| 2012-12-31 | 1.59 |
| 2011-12-31 | 2.11 |
| 2010-12-31 | 1.82 |
| 2009-12-31 | 1.58 |
| 2008-12-31 | 1.41 |
| 2007-12-31 | 1.25 |
| 2006-12-31 | 0.94 |
| 2005-12-31 | 2.18 |
| 2004-12-31 | 1.69 |
| 2003-12-31 | 1.44 |
| 2002-12-31 | 1.39 |
| 2001-12-31 | 1.92 |
| 2000-12-31 | 1.90 |
| 1999-12-31 | 1.36 |
| 1998-12-31 | 1.04 |
| 1997-12-31 | 1.52 |
| 1996-12-31 | 1.33 |
Related Metrics
About Johnson & Johnson
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato